Turning Point Therapeutics has selected R&D Logic as the corporate and portfolio FP&A solution.
June 2019 — Located in San Diego, CA, Turning Point Therapeutics has created a new generation of therapies that are different from the conventional kinase inhibitors. Their compact molecules are potentially more potent and selective medicines that also hold promise to prevent and overcome resistance.
Join us at the Westin Copley Place in Boston, MA, May 28-31, 2019.
May 2019 — R&D Logic Panel: Thursday, May 30th, at 2:15. R&D Logic Panel Discussion Topic: "Financial and Resource Management - TARGETED Reporting and Dashboards – why it matters". Review the agenda and register here.
We appreciate Casebia Therapeutics for selecting R&D Logic's R&D Time for project time collection.
March 2019 — Located in Cambridge, MA, Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer.
Ondine Biomedical selects RDL5 with DIMENSIONS for portfolio planning, corporate planning, actuals tracking, reporting and graphical dashboards.
August 2018 — Located in Vancouver, BC, Ondine is focused on the development and commercialization of their patented light activated technology, photodisinfection. Photodisinfection provides rapid antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.
RA Pharmaceuticals selects RDL5 with DIMENSIONS for portfolio planning, corporate planning, actuals tracking, reporting and graphical dashboards.
July 2018 — Located in Cambridge, MA, RA Pharma is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system.
New customer alert! Sangamo Therapeutics, the latest life science company to select R&D Time for project time collection.
June 2018 — Located in Richmond, CA, Sangamo Therapeutics believes, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases.
R&D Logic is a proud sponsor of the 2018 ABFO National Conference.
May 2018 — This year’s conference will be held in San Francisco, CA from May 29th to June 1st.
Armo Biosciences implements R&D Time for project time collection and FTE reporting.
March 2018 — Located in Redwood City, CA ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors.
Flagship Pioneering recognized R&D Logic has best in class project time collection solution, R&D Time.
Feburary 2018 — Located in Cambridge, MA Flagship Pioneering fueled by curiosity and a quest for new sources of future value, conceives, creates, resources and grows first-in-category life sciences companies.
R&D Logic releases RDL5 and Dimensions.
January 2018 — Announcing our refined innovative Life Sciences Platform to Manage your R&D Portfolio.
Exelixis is now a member of the R&D Logic Customer Community - welcome Exelixis!
October 2017 — Founded in 1994, and located in South San Francisco, CA, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.
Welcome to the R&D Logic customer community Jaguar! We appreciate your selecting R&D Logic SaaS FP&A solution.
July 2017 — Located in San Francisco, CA Jaguar Animal Health is developing a pipeline of prescription drug product candidates and non-prescription products to address unmet needs in animal health.
Warp Drive Bio recognizes R&D Logic's life sciences expertise and selects R&D Time for project time collection!
May 2017 — Located in Cambridge, MA, Warp Drive Bio operates on the core principle that nature is the most powerful inventor of new drugs, unconstrained by the boundaries of modern science.
R&D Logic is a proud sponsor of the 2017 ABFO National Conference.
May 2017 — This years conference will be held in Philadelphia from May 30th - June 2nd.
IGM Biosciences goes with the industry leader and selects R&D Logic's R&D Time for project time collection!
December 2016 — Located in Mountain View, CA, IGM Biosciences is dedicated to helping patients world-wide by creating and developing novel IgM and IgA antibodies which improve the treatment of cancer and infectious diseases.
Cerecor joins the R&D Logic customer community.
September 2016 — Located in Baltimore, MD, Cerecor Inc. joins the growing list of Biotech and Pharmaceutical companies convinced that doing business with a software company dedicated to life sciences is the right choice. Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders.
R&D Logic's R&D Time is the software of choice for Intellia Therapeutics for project time collection and FTE reporting.
July 2016 — Located in Cambridge, MA, Intellia Therapeutics is the most recent Biotech company to recognize R&D Logic's unique life sciences specialization. Intellia's combination of deep scientific expertise and clinical development experience, along with their leading intellectual property portfolio, puts them in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.
R&D Logic is a proud sponsor of the 2016 ABFO National Conference.
May 2016 — This years conference will be held in San Diego from May 24th - 27th.
Spero Therapeutics, Inc. has chosen the R&D Logic platform for project time collection, project costing and FTE reporting.
April 2016 — Located in Cambridge, MA, Spero Therapeutics is the latest life science company to select R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Spero's mission is to develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease.